Novelos Therapuetics, cancer, hepatitis Ryan McBride wrote: Novelos Therapuetics (OTC:NVLT), a Newton, MA, developer of treatments for cancer and hepatitis, announced today that it has raised $3 million through the private placement of 4.6 million shares of common stock for 65 cents per share. Novelos CEO Harry Palmin said in a statement that the proceeds of the private placement would fund the firm’s development programs through the end of the year. Permalink | Share |  E-mail Less

Biotech, cancer, clinical trials Gregory T. Huang wrote: As Luke reported a couple weeks ago, Seattle-based Dendreon is in the midst of a crucial clinical trial of its cancer drug, Provenge, against prostate cancer. Interim results from 500 patients in the trial, called Impact, are expected in October. In a conference call this afternoon, Dendreon announced its second-quarter 2008 financial stats, as well as giving a brief update on two other, smaller clinical trials of Provenge. “We’re continuing to make progress on multiple fronts, including our pipeline,” said CEO Mitchell Gold. “Our foremost priority remains advancing Provenge through the approval process.” Indeed, if the drug goes on to gain FDA approval and takes off, the commercialization plan calls for building a sales team in the U.S. and an outside partnership to distribute the drug abroad, said Gold. Dendreon has just begun enrolling patients in its NeoACT trial, which will involve 40 patients at the University of California, San Francisco, with localized prostate cancer who are scheduled to undergo a prostatectomy. The clinical trial “provides us with an opportunity to look directly at the organ, the prostate, and its immunotherapy response,” said David Urdal, Dendreon’s chief scientific officer. Another clinical trial of Provenge, called ProACT, is expected to begin later this month. It is a multi-center trial involving about 120 patients with metastatic prostate cancer. The goal, said Dendreon, is to gain new scientific insight into Provenge, and gauge its impact on patients. In a statement, Dendreon (NASDAQ: DNDN) reported a Q2 loss of $16.5 million (18 cents per share), and its quarterly revenue dropped to $26,000 from $523,000 in Q2 of 2007. The company said it holds $127.3 million in cash, cash equivalents, and investments, including $46 million raised in a stock offering in April. Comments | Permalink | Share |  E-mail UNDERWRITERS AND PARTNERS Less

Biotech, cancer, Drugs Luke Timmerman wrote: Sonus Pharmaceuticals said today it has agreed to pay $450,000 upfront, plus future milestones and royalty payments, to obtain an exclusive license from Bayer to develop a family of drugs currently in animal testing. The compounds, caspase activators, are small molecules that can trigger cell suicide in cancer cells. Bothell, WA-based Sonus (NASDAQ: SNUS) has agreed to merge with Vancouver, BC-based OncoGenex Technologies, and the deal is expected to close in the third quarter. Comments | Permalink | Share |  E-mail UNDERWRITERS AND PARTNERS Less

iPod | 4:49 | To Embed or Email: click on "Menu." You know I like to present the other side of the coin frequently, and today this regards the blind allegiance to sunscreen and fear of the sun that has been commercially developed over the past decade. There's ample research that sunlight also prevents skin cancer, and the increase in skin cancer actually correlates nicely with the increase in sunscreen! You can hear my watch my first treatise on this here, just keep in mind I shot and edited that myself, and it's a little long. The info is still good though! I hope you hop over - there are a lot of good links in that post! For the locals; I shot this at the boat ramp. Hard to understand how we have lost so much sandy beach front in only 2.5 years. Hawaiian word: Lā: sun Mālamalama a ka lā: sunlight P S We are trying a new video platform: Viddler. It has a lot of cool features - you can leave a comment right in the video - or even leave a video comment! Please check it out! (You will need to create free account at Viddler to leave a video comment.) Join us at The Reef for discussion, Reef Radio, and occasional live streaming. Support us by buying your own copy of our Beach Walks Theme music. Please check out our Blogroll page with many more links to our friends' web sites. Less

Biotech, Antibodies, Seattle Genetics Luke Timmerman wrote: Seattle Genetics, the Bothell, WA-based developer of targeted antibody drugs, said today it has started an early-stage clinical trial to look at safety of SGN-70 in 60 healthy volunteers. The drug is designed to block CD70, a protein found in abundance on activated white blood cells, but not resting cells. The target has been linked to autoimmune disorders, in which the immune system goes haywire and attacks healthy tissues. Seattle Genetics (NASDAQ: SGEN) is also developing antibodies for cancer, including SGN-35, which we profiled last month. Comments | Permalink | Share |  E-mail Less

Biotech, Provenge, Dendreon Luke Timmerman wrote: Dendreon’s David Urdal never fails to give off the impression that he’s a ballast for the company, at least in the dozens of times I’ve interviewed him in the past seven years. The even-keeled chief scientific officer has lived through all the ups and downs since he joined the Seattle biotech company back in its early days in 1995. Now Urdal, 58, is gearing up for another turning point in October. It’s from a clinical trial of 500 prostate cancer patients, known as Impact. The company (NASDAQ: DNDN) will find out if that trial can crank out the kind of evidence needed to convince the FDA it truly has a drug that can help prostate cancer patients live longer. If it does, the company will sprint to bring that drug, Provenge, to the market as the first treatment of its kind to stimulate the immune system to fight cancer cells. But if the early peek at the data—an interim analysis—shows results that could even possibly be due to chance, then everyone will have to wait in suspense one more year for a final verdict. “I think people here now can feel the moment coming,” Urdal says. “We’re within a couple of months of knowing new information, and there’s a high level of anticipation and excitement about it.” Provenge has captivated the imaginations of doctors, patients, and investors (and journalists) for years. The treatment, called an immunotherapy, or a cancer vaccine, doesn’t work like a traditional cancer drug. Blood is drawn from a patient, and some white blood cells vital to the immune system, called dendritic cells, are separated in a lab. The cells are shipped to the company and incubated with a genetically engineered protein found on prostate cancer cells, called PAP. The white blood cells are supposed to recognize the protein as an invader and recruit the immune system’s arsenal to attack tumor cells that contain it. The revved-up white blood cells are shipped back and re-infused into the patient. Without going too long on the history—that’s a book-length project—Dendreon thought it had done enough to get Provenge approved by the FDA a year ago. It asked the agency to clear the product for the sale mainly on a study of 127 men that showed it could extend patients’ lives by a median time of 4.5 months, with minimal side effects, like fever and chills. An FDA advisory panel agreed in March 2007 that the drug was safe and “substantially effective.” The next day, Dendreon became the heaviest traded stock on the entire Nasdaq exchange, rocketing from $5.22 a share to briefly more than $20 after the panel vote, as investors were betting that the FDA would follow the panel’s advice and approve the drug, as it usually does. The operative word in that last sentence is “briefly.” Dendreon crashed back to earth in May of last year. That’s when the FDA chose not to approve the drug, preferring to wait for more evidence from the ongoing 500-patient Impact trial. Almost $1 billion of stock market value evaporated in a heartbeat. So Dendreon knows about ups and downs. Now it could be in for some more. …Next Page » Comments | Permalink | Share |  E-mail UNDERWRITERS AND PARTNERS Less

Biotech, cancer, clinical trials Luke Timmerman wrote: Ariad Pharmaceuticals (NASDAQ: ARIA), the Cambridge, MA-based developer of cancer drugs, said today it has started a mid-stage clinical trial of a breast cancer treatment designed to help patients who resist Genentech’s Herceptin. The drug, an oral pill called deforolimus, is designed to block the mTOR protein, which acts like a “master switch” for cancer cells. Ariad will now receive a $15 million milestone payment from its partner, drug giant Merck (NYSE: MRK) for starting the study. The trial, of 33 patients, should wrap up in the second half of 2009. Permalink | Share |  E-mail Less

Biotech, cancer, Infinity Pharmaceuticals Luke Timmerman wrote: Infinity Pharmaceuticals (NASDAQ: INFI), the Cambridge, MA-based developer of cancer drugs, said today it has started its first clinical trial for IPI-493, an oral drug designed to block proteins that support tumor growth. The drug is meant to inhibit Hsp-90, like another intravenously-delivered compound, IPI-504, that’s being prepared for a pivotal clinical trial before the end of September. “We believe this is a step in the right direction,” said Michael King, an analyst with Rodman & Renshaw, in a note to clients, because an oral drug may be preferred by doctors and patients. Permalink | Share |  E-mail Less

Biotech, Antibodies, Rabbits Luke Timmerman wrote: About 40 miles north of Seattle, on a rabbit farm, Johnny Stine thinks he has found a disruptive force for biotechnology. He’s building a startup, called North Coast Biologics, around the idea—without a penny from venture capitalists or more than a handful of employees. Ridiculous, right? “I wouldn’t bet against him,” says Carl Weissman, the president of Accelerator, the Seattle biotech-startup incubator. Accelerator invested in Stine’s previous company, Spaltudaq, which has now raised $34 million in venture capital to develop antibody drugs. To understand Stine’s new idea, a bit of background is necessary: Genetically engineered antibody drugs, which can zero in on diseased cells while sparing healthy ones, are the fastest-growing class of drugs in the pharmaceutical industry, expected to top $26 billion in global sales by 2010. South San Francisco-based Genentech (NYSE: DNA) has become the world’s most valuable biotech company on the strength of three such drugs for cancer: Avastin, Rituxan and Herceptin. But those medicines all have origins in a technique discovered in 1975, using mouse cells. The immune system recognized them as foreign and rejected the drugs, so companies like Genentech used less mouse DNA, and incorporated more human DNA, into their antibodies. There are problems, however, with using mice, Stine says. They don’t make antibodies against some proteins that humans consider foreign, while rabbits do, he says. Rabbit antibodies have 1,000 times higher “affinity” than mice (they bind with their target on cells much more tightly and for longer). For the biotech business, that means rabbit-generated antibodies can be given in fewer shots, and at much lower doses, saving a bundle on manufacturing costs. And here’s the part that Stine says “blows people away.” With rabbits, he has developed a way to yield hundreds of antibody drug candidates in less than a month. By comparison, it can take several months for mouse methods to yield a single drug candidate, he says. He calls it BLAST (B-Lymphoblast Activation and Selection Technology). Stine isn’t the only guy who thinks rabbits may be the antibody engine of the future. …Next Page » Comments | Permalink | Share |  E-mail UNDERWRITERS AND PARTNERS Less

Biotech, cancer, VC Luke Timmerman wrote: Celator Pharmaceuticals, a biotech company with offices in Princeton, NJ and Vancouver, BC, said it has raised $22.5 million in a third round of venture financing to develop new combinations of chemotherapy drugs for cancer. Domain Associates, Ventures West, Quaker BioVentures, TL Ventures, GrowthWorks Capital and BDC Capital all participated. Kenneth Galbraith, general partner at Ventures West in Vancouver, who we have noted has his finger on the pulse of biotech in Vancouver, is joining Celator’s board of directors. Comments | Permalink | Share |  E-mail UNDERWRITERS AND PARTNERS Less

Biotech, Diagnostics, cancer Luke Timmerman wrote: Most biotech companies want doctors to write lots of prescriptions for their drugs. BG Medicine, a privately held diagnostics maker in Waltham, MA, sees opportunity in saying when that’s a waste of time and money. Take, for example, Genentech’s Avastin. The drug, the first of its kind to choke off blood supply to lung, colon, and breast tumors, is one of the world’s best selling cancer medicines, with $2.3 billion in U.S. sales last year. It costs about $4,400 a month in a low dosage, and $8,800 for a higher dose for lung cancer patients. Yet studies listed in the drug’s prescribing information show it’s effective in less than half of patients, and many people who respond initially later develop resistance. No surprise, health insurers want tests that can sort out who will benefit from such pricey drugs, and who won’t, says Pieter Muntendam, BG Medicine’s CEO. They apparently want them badly enough that they’re willing to pay high prices for tools to do it. One company, Genomic Health (NASDAQ: GHDX) of Redwood City, CA, has had success marketing a genetic test—for more than $3,400—that predicts whether an early-stage breast cancer patient is likely to relapse, and whether it’s worthwhile to take preventive chemotherapy. The market for such “molecular diagnostics” is expected to balloon from $18 billion in 2006 to $92 billion in 2016, according to Kalorama Information, a market research firm. “The big opportunity is in better matching patients with treatments,” says Muntendam. “It’s hard to convince payers to pay $100,000 for a drug that works for 15 percent of patients.” BG Medicine, for its part, envisions developing some low-price, high-volume tests for $20 to $150 apiece, and others that will cost $1,500 to $2,000, Muntendam says. The company just raised new capital this month to make it happen. BG scrapped plans to do an initial public offering earlier this year, and instead pulled in $40 million from a group of venture capitalists to help commercialize its first product and continue work to discover new biological markers of disease, or predict response to medication. The group includes Legg Mason Capital, GE Asset Management, Humana, and Flagship Ventures. BG Medicine was founded in 2000 as Beyond Genomics. It got its legs initially from doing tests for big drug companies who wanted to know early on which patients might suffer liver damage in clinical trials, so they could be weeded out, giving clinical trials a better chance at success. The effort attracted plenty of big name partners, including Pfizer (NYSE: PFE), Merck, (NYSE: MRK) and AstraZeneca (NYSE: AZN). Now BG sees its future more in marketing its own products, says Noubar Afeyan, CEO of Flagship Ventures, and executive chairman of BG Medicine. First up, the company plans to ask the FDA later this year to approve its diagnostic that spots high amounts of a protein in the blood called galectin-3. That protein is supposed to predict whether patients will die of congestive heart failure within 60 days. Another test in the works looks for a protein in the blood that’s a sign of inflammation, which is thought to make the difference between fatty buildups sticking to the lining of artery walls, or busting loose and causing a heart attack, Muntendam says. The desire on the part of insurers to control costs will continue to support the work of diagnostics companies, Afeyan says. “This notion that the health care system can offer a new drug that doesn’t really do a better job of treating disease is highly dubious. So what do you do? You identify responders from non-responders.” Drug companies aren’t really resisting the change, which is already being pushed hard by the FDA in clinical trials, Afeyan says. Thousand Oaks, CA-based Amgen (NASDAQ: AMGN) has been touting data that shows its colorectal cancer drug Vectibix works for patients with normal KRAS genes, that control cell division, but doesn’t help patients with mutated forms, or an estimated 40 percent of people. Successful diagnostics like Genomic Health and Biosite (now a unit of Inverness Medical Innovations (AMEX: IMA)) have proven to venture capitalists that there’s a lot more money than there used to be in diagnostics. “In the last 12 to 18 months, you’ve seen more exits at higher prices in diagnostics than you did in the prior 10 years combined,” Afeyan says. “Diagnostics are probably the hottest sector of all in life sciences.” If BG can get its first products on the market, and convince doctors and insurers they represent a better way to practice medicine, then maybe BG will add its name to the list of successful ‘exits,’ that Afeyan is talking about. Comments | Permalink | Share |  E-mail Less

Biotech, cancer, Devices Luke Timmerman wrote: One of the hottest cancer treatments on the market today would have died in the lab if not for a drug discovery tool made by Hopkinton, MA-based Caliper Life Sciences (NASDAQ: CALP). The story, as told by Caliper CEO Kevin Hrusovsky, goes something like this: Sugen, a small Redwood City, CA-based biotech company later acquired in 1999 by Pfizer (NYSE: PFE), was doing tests of an experimental drug in mice. Tumors of mice on the drug actually got larger than those in a control group. It didn’t make sense, because the drug, now called Sutent, was designed to block tumor proliferation and cut off blood supply. So researchers ran another test, with an optical imaging tool made by Caliper. The tool, which lets researchers see certain genes glowing in mice when they are being switched on or off, showed Sutent was actually doing what it was supposed to do. When the researchers looked more closely at the original result, the tumors still appeared bigger, but it was misleading, because they were filling up with water. With that knowledge, the researchers moved ahead with further tests. The drug won FDA approval in January 2006 for gastrointestinal tumors and kidney cancer, and generated $581 million in sales in 2007. Caliper’s sales reps lean on testimonials like that, because despite big research budgets, pharmaceutical companies are pretty conservative customers. “A lot of pharmaceutical companies won’t buy a product like this until it (the product) has a proven track record of bringing a drug to market,” says Hrusovsky. Caliper, like most companies that make picks and shovels for the gold-seeking biotechs, tends to keep a low profile. The company obtained the optical imaging tool when it acquired Alameda, CA-based Xenogen two years ago. It is now Caliper’s fastest-growing product line, with 30 percent annual growth, Hrusovsky says. Caliper expects to generate more than $140 million in total revenue this year, and to turn an operating profit in 2009. (It’s an operating profit, but not a profit according to generally accepted accounting principles, because Caliper has to take accounting write-offs for acquisitions of money-losing companies.) The company, which has about 250 of its 500 employees in Massachusetts, has been trying to fully exploit the commercial potential of the optical imaging business. Under Xenogen, the imager was sold mostly to academic researchers, Hrusovsky said, but Caliper is pushing it hard with large pharmaceutical companies. The devices aren’t cheap, at a cost of $150,000 or $350,000 for two different models, yet Novartis has bought 15, Merck has 10, and Amgen and Sanofi-Aventis have four each, he says. Cambridge, MA-based Vertex Pharmaceuticals (NASDAQ: VRTX), Wyeth, and Johnson & Johnson use it too. Caliper’s stock has been sliding much of the year, but has rebounded 53 percent since June 30, when it was added to the Russell 3000 Index. That meant Caliper shares were suddenly getting bought by mutual funds and index funds, Hrusovsky said. So where is this company headed? “We think we can get revenue close to $200 million in 2010,” Hrusovsky says. If more Sutents emerge from labs that have the optical imager, you can bet more drug companies will want it. Comments | Permalink | Share |  E-mail Less

Listen to the Full Interview Now! Introducing My Ultra Homeopathic Physician - :Kristine :Earl By Rob I’ve made use of a homeopath (or naturopath) for a couple of years now and it made such an impact in my life that I wanted to share it with you. I have been following a natural diet, using Sunrider whole foods and other supplements and just wanted to know what my inner biochemistry was like. I made it my intention to find a great naturopath and was blessed to be introduced to :Kristine and :Michael :Earl in 2004. A full 1 hour long interview I did with her is available at the end of this post. I don’t believe in accidents. My tagline and personal motto has always been … anything is possible, and nothing happens by accident … It was through a very interesting series of events that led me to :Kristine which I will write about in another post, but for the time being, just wanted to have you the reader understand that she is probably the most important person you will ever meet when it comes to your health. :Kristine is a multi disciplined ultra homeopathic physician. Enough so that we’re calling her an Ultra Homeopathic Physician. Her deep and detailed knowledge about the human body, the inner biochemistry and even the impact that your living arrangements make on your health are not to be under estimated! I could write forever and still not explain what she’s all about, so I did this 1 hour long interview with her and her husband :Michael as a way of introducing her, what she does and how she plays a role in this blog. I’ve told people for years that the results you get in your weight loss program depend on what sort of inner biochemistry you have, and that if you’re not getting results, you’d have to find out if you’re a Sugar Burner or a Fat burner and then eat according to that metabolic type. It’s your metabolic type that determines how you should eat and whether or not you’re getting your weight loss results. Well, it’s more than just that. It’s your inner biochemistry that affects your sleep, your mood, your ability to burn fat or store fat, your level of pain and even the ability to gain the kind of muscle you want to look your best. Guys: Listen Up! I train in the gym in order to build muscle. I’m a dedicated lifter and I eat and train to build maximum muscle in minimum time. What if I told you that it was things that I learned from :Kristine that allowed me the hormonal advantage to not only put on muscle, gain weight, but also to keep it? Everything that I do, everything that I eat, and all the little tricks that I’ve learned over the years, I’ve put in place because it’s muscle that looks good, keeps you strong, keeps you healthy, burns more fat, and keeps you pain free (if you’re training properly). I went to :Kristine because I wanted to improve my inner biochemistry to do all these things in a more efficient and effective manner. and now you can too… :Kristine will be pouring out all her knowledge on how your body works and what you need to know to make educated decisions in your health. Articles @ BetterHealthAnswers.com Seminar.BetterHealthAnswers.com UltraHomeopathy.com Tests.InnerBiochemist.com The Cellular Patch Testimonials Forum.InnerBiochemist.com Blog.InnerBiochemist.com :Kristine, The Inner Biochemist, Along with her husband :Michael who will interpret her science and present you with the simple version, will give you the reader of this blog all the information you’d ever need so that you can eat for your metabolic type, eat for your inner biochemistry and finally put an end to your searching. Here is a one hour long interview I did with :Kristine and :Michael :Earl along with all the links that they share. Visit the links after or as you’re listening to the interview. They will open in a new window so that you may continue to listen while you’re reading. You’ll hear :Kristine and :Michael’s son Neoh interact in the conversation as well. This is a real couple being interviewed from their home, and just like any child, Neoh wanted some attention of his own. Stop experimenting with various supplements and weight loss programs, find out what is going to work for you right here, and right now. Stop wasting your money and your valuable time, get the answers and get the job done. Listen to the Full Interview Now! Less

Brief Version Recorded Intro Full Length Audio Intro The Inner Biochemist The Simple Solution My Mission–is–My Passion: - Healthcare Revolution listen to my MISSION here…The Full Version …We don’t experience migraines because of a deficiency in Tylenol 3. …We don’t experience depression because of a deficiency in Prozac. …Our child doesn’t have ADHD because they were born without Ritalin. …We don’t experience cancer because of deficiencies in “Chemo”… My mission is to change individual health care. I would like to see everybody understanding real health. What is Real health? Is it the absence of symptoms? No. Health is when a man becomes natural. What is natural? It is easy spontaneous and without effort. The word “SAHAJ” in Sanskrit means “what is natural, what is innate, in anything’s being.” When you are your natural self and don’t have any obsession or compulsion, you are not bothered about the results of your actions. That is what health is. Health, is freedom from pain in the physical body… Having attained a state of true well being …Freedom from turmoil and conflict on an emotional level …Having attained as a result, a dynamic state of serenity and calm. Freedom from selfishness in the mental sphere, having as a result: total unification with truth. …The mental level is the most important level for us human beings. It is the level where the spiritual content of a person emerges. That which is the true essence. We are all here for evolving in consciousness and if the inner tools of obtaining a higher consciousness are broken or disturbed then the whole purpose of evolution in consciousness is lost. Then what is the meaning of life? An absolute healthy mind is expressed by a person living in a continual spiritual bliss. Daily revealing new creative ideas… Expressed in very clear ways, always in the service of others. That is health. I want to see that when your child experiences an earache, he or she is given natural remedies to help heal. Not antibiotics. And true understanding of the biological conflict that causes that symptom. I want to see that an allergy is cleared naturally, instead of being “treated” or suppressed with Claritin or whatever else is available in the pharmacy. Antibiotics, Pain killers, allergy medications, antacids and laxatives are all used and well over abused for the wrong reasons. We just need to understand why we are experiencing that certain symptom - and then follow the road to health. You don’t experience a migraine because of deficiency of Tylenol 3. You don’t experience depression because of deficiency of Prozac. Your child doesn’t have ADHD because of deficiency of Ritalin. You don’t experience cancer because of a deficiency of chemo. I found this snip in an ancient text of Sumeria called “The Sacred Script of the Covenant“: “Honor your body, which is your representative in this universe. It’s magnificence is no accident. It is the framework through which your work must come true, through which both the spirit and “the spirit within the spirit” speak. The flesh and the spirit are two phases of your actuality in space and time. Who ignores one, falls apart in shambles. So it is written…” The human being was originally designed to function harmoniously, and compatible with the environment. Since human beings are gifted with consciousness and awareness, they carry great responsibility both for their own benefit and for that of the cosmos, to live accordingly to the laws of nature. But what we see is that most individuals, instead of enjoying an increasingly vibrant degree of health from generation to generation, are experiencing a continuous decline in heath. Why? For 2 reasons, 1: Humans are in violation of the laws of both nature and health. 2: Mankind has gradually lost an inner awareness which would have enabled correct perception of the laws of nature and health, which still must be respected. So here I am to help you get out of this vicious cycle! I believe that this universe would not be the same without all the individuals that are born… We are all very unique and all of us have something very valuable to offer — and we have to help each other to reach our full consciousness. All of us are here with a mission; there is no reason why anybody should be depressed, but in truth, millions of people are. Why? So let’s engage in this journey together, and untangle health, layer by layer, and reach our full potential together. That is my mission. …I hope you have found this article on MY MISSION informative! Please post your comments and questions below, simply by scrolling to the end of this article… So make sure you follow us closely - and if you have any questions - or future areas of interest - go to my forum at The Inner Biochemist Question and Answer Section Listen to an entire One Hour Long Interview with :Kristine:Earl - The Inner Biochemist …Please help me change and heal the world! Spread the word… …My Mission–is–My Passion: listen to my MISSION here… …Because if you don’t take care of your body, where will you live? www.TheInnerBiochemist.com Comment on this article below, or go to my forum to ask further questions, and see more answers. Please see my POINT-AND-CLICK ONLINE TESTS for amazing accuracy and health… …because they get RESULTS   The Best a Person Can Get - Your Natural, Scientific Alternative to Drugs and Surgery   © 2006-2007 BY::Kristine:Earl::BetterHealthAnswers The Fine Print Less

Good enough for the British Royals? A Brief Introduction to Ultra Homeopathy! The Inner Biochemist The Simple Solution …I bet you didn’t know that Ultrahomeopathy is the only medicine used -yes insisted on- by the British Royal family. …I bet you didn’t know that Ultrahomeopathy is the only medicine that reverses genetic decline… …I bet you didn’t know even simple homeopathy has had amazing results during epidemics… …I bet you didn’t know that every generation experiences genetic decline in North America… From Infertility and conception difficulties, to massively expanded birth difficulties and early childhood disease - including allergies and asthma, to dramatic obesity. You’ll understand in future articles why this genetic weakening is happening - and its outcomes. Now - The internet is amazingly full of misinformation on homeopathy. Why? Because an enormous multi-billion industry that directly influences 150 different countries is very threatened by the success of homeopathy — or any other competitor. The Truth About Homeopathy is that it definitely works, even if the internet is full of falsified information about it (there is a reason for that - see below) - it is the highest form of medicine, nothing can make you feel better, and those who are in good homeopathic hands say it is nothing short of miraculous… that is The Truth About Homeopathy… Now here’s the Why: Examples of efficacy in mass pandemics: When we had the Spanish flu epidemic in 1918, 22 million people died world wide of this virus. Here are some interesting facts: In the US alone, 500,000 deaths were caused by this epidemic. (In a future article, I will explain how viral epidemics work….) Dr Dean W A Pearson, of Philadelphia and Hahnemann College collected data of 26,795 cases of influenza, treated by homeopathic physicians, which showed a mortality rate lower than 1.05%. The mortality rate among those treated by Allopathic medicine - without homeopathic medicine - was 30% to 40%. Now ask yourself: Which risk might -I- like to be exposed to? 1% or 40% chance of death? EXAMPLE: …So what is homeopathy? And what is the the advanced Ultrahomeopathy? DEAR READER: This article is the introduction to another specialty that I have. It is literally a Health Care Revolution! After this introduction, I will refocus on the Inner Biochemistry healthcare revolution for the next few months… as I did in the introductory article about Vitamin C and Calcium. The next article is about “Sugar Burners”… What Is Homeopathy? …So what is simple homeopathy? And what is Ultrahomeopathy? It is a system of medicine founded by Dr Samuel Hahnemann, who lived between 1755 and 1843 in Germany. It is based on a new principal that “like cures like”. What does this mean? A medicine capable of producing certain effects when taken by a healthy human being is capable of curing any illness that displays similar effect… This is known as the “law of Similimum.” A painting of Dr. Samuel Hahnemann - founder of Homeopathy - observing the horrors of “Allopathic Medicine” as it bludgeons and poisons patients to death - even for profit*: (*Note in the US, medical doctors are currently forced to sign contracts with HMO’s guaranteeing patients will not be told of new and better treatments and methods. Thus preserving HMO profits. That’s on top of one of the what is already one of the worst systems of health care per dollar spent. In the area of Cancer alone, new treatments have been received with SWAT Teams, attack dogs, lab burnings, and over 300 cancer-research scientists “dead” over the past 5 years - all under suspicious circumstances… the profits of this industry are enormous - and it stops at nothing to protect them. Cancer books are routinely forced out of circulation by the US Government - without regard to “freedom of the press” or constitutional rights…This is why it’s a big area folks. Better information is often fought savagely, to protect profits. In fact, it’s hard to find good health information on the Internet…a sad comment on the state of democracy, and ethics, but let’s move on with the article…) For example, if a healthy person takes a dose of arsenic, he will develop vomiting, diarrhea, a rapid pulse and prostration. His skin will become cold, and he will grow very anxious. If he continues using arsenic, his nose will be running, he will have a heavy head, cough, and bronchial catarrh. Later he will develop even more specific disturbances of the skin and nervous system. He will have a burning sensation all over, which is relieved by warmth. He will have frequent thirst for sips of water; he will have fear of death, restlessness, and the worsening of symptoms at noon and midnight. Now if any of these symptoms are experienced by a sick person, they can be treated by Arsenicum…. Because you can see that the original substance has attacked the physical level (runny nose, catarrh, cough, etc.) The emotional level (restlessness) and the mental level (fear of death, and prostration) Now - follow me carefully here - because this part is hard for most people to understand: So what is “Arsenicum”. It is arsenic diluted in a special way, take one part arsenic to 99 parts water and mix and shake well ( succussing is extremely rigorous shaking ) … Then take one part of this mixture and mix it again with 99 parts of water - and repeat… This is called dilution and potentization. When you repeat this process 12 times you have *not one atom* of the original substance left in the new mixture. According to the law/constant of Avogadro: To give you some idea how small these doses are - consider a concept of chemistry known as Avagadro’s number: This number is an extremely large number that becomes a negative number, it’s “602″ with twenty one 0’s after that! That represents the number of particles present in any given quantity of substance. It is also known as a “mole”. When you dilute more than 12 times there can’t be any atom left of the original substance. Potencies used commonly today, are 6C, 30C, 200C, 1000C, 10000C and 50000C. EXAMPLE: To give the reader some idea of how extremely diluted, let’s take for example a dilution of 100000C. Let’s describe it in terms of a numerical fraction. Avogadro’s number would correspond roughly to a dilution represented by 1/1000… to a total of 24 zeroes. A potency of 100000C would be represented by a dilution of 1/100000…to a total of 100,000 ZEROES! Inconceivably far beyond the point at which not one atom of original substance is left. Therefore, it has been said that “poison is the remedy for poison…” Hahnemann postulated this principle as “Similia Similibus Curentur” meaning roughly “like is cured by likes.” Ultrahomeopathy is the only medicine where the remedies are tested on human volunteers, or “provers”, to illicit the symptoms they will produce. So now understand that any medicine you put in your body, ie. “Tylenol, Aspirin, Zantac” etc which you take for a symptom, will cause other symptoms…These other symptoms are called by pharmaceutical companies “side effects”. They are not side effects - they are primary effects of the drug quite purposely misunderstood by a for-profit industry. They say “side effects”, because these are the effects that we are not interested in seeing, but everybody who takes that individual drug experiences a multitude of symptoms. It will cause symptoms on the physical level, emotional level, and mental level - even if you just take it for the physical level…depending on your susceptibility level to that substance. EXAMPLE: Taking Tylenol for a headache will come with maybe a bit of nausea, sleepiness, and often constipation. Which is the primary effect? And which is the secondary effect? To look at it accurately - They are all primary effects. So take for example common side effects of pharmaceutical drugs, headache, nausea, constipation, dizziness, death. This has become the number one cause of death in North America - right now. …Depending on how susceptible you are to a substance that is how you will react. The individuals who are extremely susceptible to a drug can have a real anaphylactic shock from something as simple as aspirin. What happened to the Hippocratic Oath of “above all, do no harm…”? …As in the 3rd law of Newtonian physics, “for every action, there is an equal and opposite reaction?” Allopathic medicine ignores this principle. How To Improve Sleep or Insomnia With Homeopathy EXAMPLE: Let’s take insomnia. We take a sleeping pill for that, so if you can’t sleep you take a pill that will knock you out. You sleep. This is the “action” of the pill, but the “re-action” of your body to that pill is wakefulness - as anybody who has taken a sleeping pill knows. In general “the next night” you have even more problems sleeping, you take one more pill - which won’t knock you off as hard as the 1st one - and in time the affect of the pill will get less and less and you will need stronger and stronger pills - or more and different kinds of pills. …This is the approach to sleeplessness coming from an Allopathic point of view… they are trying to set forth an action and trying to ignore the equal and opposite reaction. Over a lengthy period of time, you will definitely get increased sleeplessness. The homeopathic approach to the -same symptom- using the earlier “like cures like” - gives a remedy to increase the symptom - a remedy that in a sleepy person would create sleeplessness. Let me explain, by working with the “Law of Similars” the Ultrahomeopath uses the principle of equal and opposite reaction to bring healing. Giving the patient the correct remedy causes sleeplessness - which is an action. The system meets this with an equal and opposite reaction - which is sleepiness. Together - both reactions harmonize into a healing reaction. Ultrahomeopathy is a reactive medicine, one that places the healing impact on the equal and opposite reaction rather than an active medicine, such as Allopathy, that places the forces of cure on the first medicine action, and calls the equally potent reaction, “a side effect.” Can Coffee Improve Sleep? EXAMPLE: A potential remedy for sleeplessness in a good Ultrahomeopathy case-taking is “Coffea” - or coffee in diluted and sucussed or potentized form. Do you understand these laws at play now? If not, please go back and reread this section until it “sinks in”. When you “get it” - then you’ll understand how powerful this is. There are other remedies used for sleeplessness, you have to use the correct remedy that fits the picture of a person on the physical, and emotional and mental level - at the same time. Some practitioners do not understand this principle, so they feel like, that homeopathic remedies can be used like allopathic drugs - which couldn’t be further from the truth. ie. The watered-down, garden-style variety of “health food store homeopathy” - with the thinking that “This remedy is for headache, this remedy is for trauma, this remedy is for colds, this remedy is for allergies.” We’ll have further articles in this area - but this point is key. Improperly used homeopathic remedies can be as damaging as Allopathic drugs. Don’t play games with this. Self-prescribing is sure to hurt you. Example: Take a health food store or beginner homeopath “combination” or “cocktail” of remedies for your asthma - and all 9 will work! 1 for you, the other 8 against you. Get it? At first it might seem “that it worked” as in Allopathy, and later you will have a bigger, future disease to pay… In Ultrahomeopathy, we look at what is different, what makes each person unique, so we can treat the patient with individual precision…. Allopathic medicine looks for what is the same between patients and then applies a uniform treatment to the disease. When I get a patient and they say they are experiencing depression, I always ask for more information - what else are they experiencing? They usually experience a multitude of -simultaneous- symptoms like indigestion, head ache, and some menopausal symptoms. All the symptoms should be considered by the Ultrahomeopathic physician and instead of giving one “canned” remedy for depression, asthma, or headache - we have to treat the whole person with only 1 remedy, of an available 10,000 - instead of guessing and giving a remedy. We treat the whole person. It is not easy but that is what Ultrahomeopathy is. It’s a process of intricate analysis that has hyper-precise results….And takes years of training to accomplish. EXAMPLE: Now think of a multi billion dollar pain killer industry, think of a head ache. IF you take a painkiller for a head ache, does that actually cure that head ache? Of course not. It merely separates you from the sensation of pain. That’s all. It’s not even addressing the cause. Ultrahomeopathy is the only form of medicine that can improve the genetics of future generations. There is research that shows that 3 generations treated in a row with Ultrahomeopathy will totally erase normal childhood diseases at the genetic level. Ultrahomeopathy deals with anything, from a mild ear ache, to a crisis, from infertility to degenerative disease, including cancer. Most importantly — without suppressing your disease. (Suppression guarantees larger future disease - it is unfortunately the favorite form of both Allopathic and certain Natural treatments in North America at this time. More on this in a future article. Sign up for this blog in the upper right hand corner - and Look for the article on “Health Suppression - How Current Treatments = guaranteed future, larger diseases - and increasingly weaker generations of kids”.) Ultrahomeopathy is the only form of medicine that can address disease at it’s deepest level - it’s cause. The name of the disease does not matter, because we treat the person with very unique individual symptomatology - and the treatment is done without suppression of the disease, instead, intra-cellular cause resolution. This is something I will explain later in a future article…Again - It is important to Sign up for this blog in the upper right hand corner - and Look for the article on “How Current Treatments = guaranteed future, larger diseases - and increasingly weaker generations of kids”. Now do you understand why the Royal Family and Billionaire Rock Stars insist exclusively on Ultrahomeopathy? Good enough for the British Royals? A Brief Introduction to Ultra Homeopathy! …Why those with money and informed opinions are Shunning North-American medicine? SUMMARY: The Truth About Homeopathy is that it worked amazing well in epidemics/pandemics that made history, it invented vaccination - and does it properly (unlike all the current autism-linked vaccine knockoffs/ripoffs - which for-profit break all the original rules as intended by homeopathy) - and if you really want to feel well, this is the highest form of medicine… Good enough for the British Royals? A Brief Introduction to Ultra Homeopathy! Please post your comments and questions below, simply scrolling to the end of this article… So make sure you follow us closely - and if you have any questions - or future areas of interest - go to my forum at The Inner Biochemist Question and Answer Section Listen to an entire One Hour Long Interview with :Kristine:Earl - The Inner Biochemist …Please help me change and heal the world! Spread the word… …My Mission–is–My Passion: listen to my MISSION here… …Because if you don’t take care of your body, where will you live? www.TheInnerBiochemist.com Comment on this article below, or go to my forum to ask further questions, and see more answers. Please see my POINT-AND-CLICK ONLINE TESTS for amazing accuracy and health… …because they get RESULTS   The Best a Person Can Get - Your Natural, Scientific Alternative to Drugs and Surgery   © 2006-2007 BY::Kristine:Earl::BetterHealthAnswers The Fine Print Less

Biotech, Stem Cells, Harvard Luke Timmerman wrote: GlaxoSmithKline, the world’s second-biggest drugmaker, said it agreed to invest $25 million over five years in the Harvard Stem Cell Institute for a collaboration to develop new treatments. London-based Glaxo (NYSE: GSK) said the collaboration will spur research at Harvard and at least four affiliated hospitals to study neuroscience, cancer, diabetes, obesity and musculoskeletal diseases. “We have carefully chosen the Boston biomedical community to collaborate with on this important venture. It has the highest concentration of leading stem cell scientists,” GSK’s head of drug discovery, Patrick Vallance, said in a statement. Permalink | Share |  E-mail Less

Biotech, cancer, Life Sciences Luke Timmerman wrote: Cell Therapeutics, the Seattle-based developer of cancer drugs, said today it has raised $44.5 million in convertible debt and warrants from a single institutional investor it didn’t name. The notes, which come at 18.3 percent interest and come due in 2011, can convert to stock if Cell Therapeutics’ shares climb above 79 cents. Late Friday, the company said it needed to raise cash within 30 days to keep operating. Shares in the company closed yesterday at 38 cents. Comments | Permalink | Share |  E-mail Less

Biotech, cancer, people Luke Timmerman wrote: Llew Keltner flies about 600,000 miles a year. The CEO of Light Sciences Oncology insists he can’t imagine doing his job any other way. There are doctors in about 30 countries testing his company’s experimental drug/device combo treatment in clinical trials of cancer patients. He meets the physicians in person, twice a year, to talk about the product and learn how it’s being used. Then there are always meetings to talk about it with investors and potential partners. He visits the company office only once or twice a quarter, he says. “How could I go into those meetings with investors if I didn’t do that?” Keltner says. “It’s invaluable experience.” Still, I was able to book an hour this week to meet the highly-mobile Keltner at his company’s Bellevue, WA headquarters, a week after he raised $40.1 million in venture capital. Most of what’s been written about the company has focused on the “it-failed-to-go-public” angle, yet it turns out Light Sciences Oncology has a much more important news event coming up. After 13 years in business, it will find out in a few months whether the company’s light-infusion technique can actually help cancer patients live longer. It’s been a long time coming for a company supported for years by Craig Watjen, the treasurer from the early days of Microsoft, and more recently, an array of venture capital firms that includes Essex Woodlands Health Ventures, Johnson & Johnson Development Corporation and Novo A/S. The market they are pursuing initially, liver cancer, affects an estimated 19,000 people in the U.S. each year, although the technology could be able to be applied to many more tumor types than that, Keltner says. To understand why, some background is required. The company’s product, called LitX, is attempting to become the first treatment of its kind. The system works by using a light-emitting diode, guided by a biopsy needle, which doctors can thread inside a solid tumor with the help of an ultrasound or CT imaging machine. The patient is then injected with an inactive chemical drug called talporfin sodium. Once the light is turned on, powered by cheap AAA batteries, it activates the drug to kill tumors within a limited wavelength, sparing nearby healthy tissue. The light stays on for almost three hours while the patient can watches TV or reads a magazine, and then goes home. The company has passed some early clinical trials that show tumor shrinkage, yet has said little about it, Keltner says, because he doesn’t want to raise false hope among patients about a treatment that’s not yet available. Now, he feels he can “loosen up a bit,” because LitX has advanced to the final proving ground, a Phase III trial of liver cancer, which could provide evidence needed to bring the product to market. The company began recruiting 200 patients for the test of LitX against liver cancer in November 2006. It chose that disease because …Next Page » Comments | Permalink | Share |  E-mail UNDERWRITERS AND PARTNERS Less

Biotech, cancer, Provenge Luke Timmerman wrote: Dendreon, the developer of treatments to stimulate the immune system to fight cancer, said today it expects interim results in October from a clinical trial of 500 men with terminal prostate cancer. The Seattle-based biotech company (NASDAQ: DNDN) said it hopes to use the data, which looks at whether Provenge can help men with the disease live longer, to support its application to the FDA to market the drug. A final analysis of the data expected in the second half of 2009 has a greater likelihood of success, although the interim analysis could allow the company to bring the therapy to the market faster, the company said. Dendreon shares rose 3.4 percent, to $6.02 at 10:09 a.m. Eastern time. Comments | Permalink | Share |  E-mail Less